English | Español
Patient Daily | Dec 9, 2025

Lilly and Novo Nordisk drug pricing changes open market opportunities for rivals
Patient Daily | Dec 9, 2025

Penn Medicine appoints new leaders aiming to reshape undergraduate and graduate medical education
Patient Daily | Dec 9, 2025

Prasad memo prompts debate as FDA sees leadership changes and new drug data emerges
Patient Daily | Dec 9, 2025

Bristol Myers Squibb postpones Alzheimer’s psychosis drug trial results after site irregularities
Patient Daily | Dec 9, 2025

UTHealth Houston researchers secure nearly $10 million for diverse state-backed cancer initiatives
Patient Daily | Dec 9, 2025

International Arthritis Foundation urges changes to 340B drug pricing program
Patient Daily | Dec 9, 2025

Early-stage biotech firms urged to address tariff risks in planning
Patient Daily | Dec 9, 2025

Harmony's EPX-100 reduces seizures by half in Dravet syndrome Phase III trial

Trending
+ Pharmaceuticals
Patient Daily | Apr 5, 2026

Amplifon announces $2 billion acquisition of GN Hearing in strategic shift
Patient Daily | Apr 7, 2026

ProPublica examines impact of RFK Jr.'s vaccine policies on childhood disease risks
+ Regulatory
Patient Daily | Apr 9, 2026

Reason Foundation commentator on vaccine liability: 'Exposing vaccine makers to the machinations of trial lawyers will stymie the development of innovative vaccines'
+ Regulatory
Patient Daily | Apr 8, 2026

Columbia University Professor Masia on 340B: '340B has become a drug mark-up program. Hospitals buy drugs at low cost and sell them high'